-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FMzazjmWifqMu0jY2TTSgJUhMbaUteavOLXzk4NF3jNBnegP3OSvG/pgF5QfUk5R bG8Ki6Lu+Qswznq0n9NL0w== 0000950135-05-001469.txt : 20050316 0000950135-05-001469.hdr.sgml : 20050316 20050316120055 ACCESSION NUMBER: 0000950135-05-001469 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20050310 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20050316 DATE AS OF CHANGE: 20050316 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ANTIGENICS INC /DE/ CENTRAL INDEX KEY: 0001098972 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 061562417 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-29089 FILM NUMBER: 05684053 BUSINESS ADDRESS: STREET 1: 630 FIFTH AVENUE SUITE 2170 CITY: NEW YORK STATE: NY ZIP: 10111 BUSINESS PHONE: 2123324774 MAIL ADDRESS: STREET 1: 630 FIFTH AVENUE SUITE 2170 CITY: NEW YORK STATE: NY ZIP: 10111 8-K 1 b54129aie8vk.htm ANTIGENICS INC. e8vk
 

 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

March 10, 2005
Date of Report (Date of earliest event reported)

ANTIGENICS INC.
(Exact name of registrant as specified in its charter)
         
 
DELAWARE   000-29089   06-1562417
(State or other jurisdiction
of incorporation) 		  (Commission
File Number) 		  (IRS Employer
Identification No.)
     
630 Fifth Avenue, Suite 2100    
New York, NY 10111   10111
(Address of principal executive offices)   (Zip Code)

212-994-8200
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

 

 

Item 1.01 Entry into a Material Definitive Agreement

     On March 10, 2005, the Board of Directors of Antigenics Inc. (the “Company”) ratified the recommendation of the Compensation Committee and awarded Garo Armen, Chairman and CEO, a cash bonus of $174,300 under the Company’s Executive Incentive Plan, a stock option grant of 300,000 shares under the Company’s 1999 Equity Incentive Plan and set his base salary for 2005 at $440,000. In addition, the Board of Directors ratified the recommendation of the Compensation Committee to award Pramod Srivastava, Founding Scientist, a cash bonus of $135,000 and a stock option grant of 120,000 shares under the Company’s 1999 Equity incentive Plan.

     On February 10, 2005, the Compensation Committee awarded the following cash bonuses to the Company’s named executives:

         
Peter Thornton, Sr. Vice-President and Chief Financial Officer
   $ 49,583  
Russell Herndon, President, Commercial Operations
   $ 104,000  
Renu Gupta, Sr. Vice-President, Development
   $ 117,000  
Roman Chicz, Sr. Vice-President, Research & Preclinical development
   $ 39,750  

     All bonus awards are recommended based on achievement of goals and benchmark data.

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     
  ANTIGENICS INC.
     
     Date: March 16, 2005   By:      /s/ Garo H. Armen
     
  Garo H. Armen, Ph.D.
Chairman and Chief Executive Officer

 

-----END PRIVACY-ENHANCED MESSAGE-----